Maxalt (Rizatriptan Benzoate)

Rizatriptan selectively stimulates serotonin 5‑HT1B and 5‑HT1D receptors on cranial blood vessels and trigeminal nerve endings. This action causes vasoconstriction of dilated intracranial arteries and blocks the release of inflammatory neuropeptides, interrupting the migraine cascade and providing pain relief.

The dosage of Maxalt is individualized by the prescribing healthcare professional based on the patient’s clinical condition, severity of migraine, and prior response to therapy. Patients should follow the prescriber’s instructions and not exceed the recommended amount.

Safety data for rizatriptan in pregnancy and lactation are limited. The drug should only be used if the potential benefit justifies any potential risk to the fetus or infant, and the decision must be made by the treating physician in consultation with the patient.

To request Maxalt, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Maxalt (rizatriptan) belongs to the Triptan class, which is generally more effective for moderate to severe migraine attacks than simple analgesics. Compared with other triptans, rizatriptan has a relatively rapid onset of action and a convenient oral tablet formulation, though individual response may vary.

Store Maxalt tablets at ambient temperature, below 25 °C, in the original packaging to protect from moisture and light. Keep the product out of reach of children and do not use after the expiry date printed on the label.

Maxalt is taken orally, usually with a glass of water. The tablet should be swallowed whole and not chewed or crushed. It is typically taken at the first sign of a migraine attack, and a second dose may be considered after at least two hours if needed, according to the prescriber’s guidance.

Serious risks include coronary artery vasospasm, myocardial ischemia, stroke, and serotonin syndrome, especially when combined with other serotonergic drugs. Patients should seek immediate medical attention if they experience chest pain, severe hypertension, or signs of an allergic reaction.

Maxalt is contraindicated in patients with a history of coronary artery disease, uncontrolled hypertension, severe hepatic impairment, or known hypersensitivity to rizatriptan or any component of the tablet. It should also be avoided in individuals who have taken ergotamine-containing medications within the previous 24 hours.